Cyclic di-GMP as an Antitoxin in Biofilm Persistence
2026-09-09
Liao et al. identify cyclic di-GMP as a small-molecule antitoxin that restrains the genotoxic toxin HipH during biofilm development. The study links adhesion-stage signaling to DNA double-strand breaks, genome instability, and antibiotic-persistent cells, providing a mechanistic framework for biofilm formation regulation beyond simple diffusion or nutrient-limitation models.
AMPK–SQSTM1 Feedback in Metabolic Stress
2026-09-08
The reference study identifies a double-positive feedback loop between AMPK and SQSTM1/p62 that coordinates NRF2 activation with energy-stress adaptation during metabolic stress. Its mechanistic framework links lysosomal pH, calcium release, ROS, TFEB/TFE3, and KEAP1 degradation, while defining experimental boundaries for translating these findings to sensory and pain-related research.
Dacarbazine Workflows for Cancer Drug-Response Assays
2026-09-08
Build more informative Dacarbazine assays by separating growth inhibition from true cell killing, rather than relying on a single viability endpoint. This practical guide covers fresh-solution handling, time-resolved screening, comparative oncology models, and troubleshooting for melanoma, lymphoma, and sarcoma research.
Sulfaphenazole: A Dual-Use Assay Decision Guide
2026-09-07
Sulfaphenazole is both a selective CYP2C9 inhibitor and a sulfonamide antibacterial research tool. This guide translates its dual pharmacology into practical assay decisions, controls, concentration ranges, and interpretation limits.
CD36 Lipid Signaling Drives Immune Escape in AML
2026-09-05
Guo et al. identify a CD36-dependent, non-canonical lipid signaling program that enables acute myeloid leukemia cells to suppress T-cell activity and resist decitabine therapy. Their data connect OxLDL sensing, palmitate transfer, TLR4–LYN–MYD88–NF-κB signaling, and lipid-lowering treatment, providing a mechanistic framework for studying immunometabolic resistance in AML.
DFCP1 Controls Starvation-Driven ATGL Lipolysis
2026-09-05
The reference study identifies DFCP1 as a nutrient-sensitive regulator of lipid droplet catabolism, showing that it recruits ATGL to droplets during starvation and limits lipolysis by reducing ATGL dissociation. Its combination of pharmacological pathway dissection, interaction analysis, and dynamic imaging provides a mechanistic framework for studying how lipid storage organelles balance fatty-acid release with cellular protection.
Miltefosine Activates ERK in Leukopenia
2026-09-04
The reference study identifies Miltefosine as a preclinical promoter of neutrophil differentiation and recovery from irradiation-induced leukopenia. By combining cellular assays, a murine model, transcriptomics, network pharmacology, molecular docking, and pathway inhibition, the authors link these effects to activation of the Ras/MEK/ERK cascade.
Exosomal SNORD52 Activates JAK2/STAT6 in HCC
2026-09-04
The reference study identifies hepatoma cell-derived exosomal SNORD52 as a transferable regulator of macrophage behavior in hepatocellular carcinoma. Its experiments connect SNORD52 uptake by THP-1 macrophages with M2 polarization and increased JAK2/STAT6 pathway activity, providing a mechanistic framework for studying tumor–immune communication.
Dye Models for Small Tissue Biopsies in Pathology
2026-09-03
The reference study evaluates five dyes as pre-processing markers for very small biopsy specimens and shows that merbromin, hematoxylin, and Alcian blue improve tissue visibility during laboratory preparation. Hematoxylin was the most practical choice because it combined improved observability with lower toxicity and no apparent interference during routine slide examination.
Rocilinostat (ACY-1215): From Target to Assay
2026-09-03
Rocilinostat (ACY-1215) is a selective HDAC6 inhibitor whose value extends beyond potency alone. This article connects its multiple myeloma applications with a causally rigorous SMPD4–ceramide–primary cilia study, showing how to design better mechanistic assays without overstating cross-domain evidence.
GS967: Cardiac Late Sodium Current Workflows
2026-09-02
GS967 enables controlled investigation of abnormal late Na⁺ influx across ventricular myocytes, aging models, and isolated-heart preparations. Its concentration-dependent activity and reported antiarrhythmic performance make it useful for connecting cellular sodium current inhibition with repolarization, calcium handling, and arrhythmia phenotypes.
SPP1–M2 Macrophage Crosstalk in ESCC
2026-09-02
A 2024 British Journal of Cancer study identifies SPP1 as an active driver of oesophageal squamous cell carcinoma progression rather than merely a prognostic marker. The work connects SPP1 from ESCC cells to CD44/PI3K/AKT-dependent macrophage recruitment and M2-like polarization, with downstream VEGFA and IL6 supporting tumour growth.
Difloxacin HCl: Applied Assays and Workflow Guide
2026-09-01
Difloxacin HCl supports two complementary research workflows: phenotypic antimicrobial susceptibility testing and exploratory multidrug resistance reversal studies. This guide connects DNA gyrase–based bacterial assays with carefully controlled neuroblastoma experiments while distinguishing established product applications from mechanistic hypotheses inspired by mitotic checkpoint research.
HyperScribe™ Poly (A) Tailing Kit for mRNA Workflows
2026-09-01
Build more reliable post-transcriptional RNA workflows for transfection experiments, micro-injection, and protein-expression assays. The HyperScribe™ Poly (A) Tailing Kit combines E. coli Poly (A) Polymerase with ATP and MnCl2 to support consistent tailing of HyperScribe™ T7-generated transcripts while leaving room for sequence, cap, and nucleoside-modification optimization.
BML-277 for Chk2 DNA Damage Response Studies
2026-08-31
BML-277 provides a reversible, ATP-competitive way to interrogate Chk2 signaling across biochemical assays, irradiated T-cell models, and emerging nuclear cGAS studies. Its nanomolar enzyme potency and micromolar cellular response range support dose-separation experiments that distinguish direct kinase inhibition from downstream radiobiological effects.
462 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page